Trial · NCT07886905
Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer
NCT07886905, Phase 2, Not yet recruiting, Washington University School of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer. Trials, record NCT07886905. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07886905
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer
- NCT number
- NCT07886905
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 12 participants, estimated
- Lead sponsor
- Washington University School of Medicine
- Conditions
- Anaplastic Thyroid Carcinoma, Thyroid Cancer, Thyroid Carcinoma
- Interventions
- Dabrafenib, Trametinib, Pembrolizumab, Pulsed Stereotactic Ablative Radiotherapy, Ethos
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of 30-day mortality | Within 30 days after any administered PULSAR fraction (up to approximately 9 weeks) | Defined as death considered possibly, probably, or definitely related to PULSAR-DT +/- pembrolizumab occurring within 30 days after any administered PULSAR fraction. The treatment-related mortality rate will be calculated as the number of participants experiencing a qualifying death divided by the total number of participants in the Safety Analysis Set (all enrolled participants who receive at least one fraction or dose of any treatment, including PULSAR, dabrafenib, trametinib, or pembrolizumab) and will be presented with an exact binomial 95% confidence interval (CI). |
| Primary | Objective response rate (ORR) at 1st restaging | At 1st restaging (estimated to be 4 weeks) | ORR is defined as the proportion of participants achieving a confirmed complete response (CR) or partial response (PR) as assessed by RECIST 1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. |
| Primary | Objective response rate (ORR) at 2nd restaging | At 2nd restaging (estimated to be 13-14 weeks) | ORR is defined as the proportion of participants achieving a confirmed complete response (CR) or partial response (PR) as assessed by RECIST 1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. |
| Secondary | Feasibility as measured by the total percentage of participants who are able to undergo surgical resection following completion of neoadjuvant PULSAR-DT +/- pembrolizumab | Baseline until completion of surgery (total estimated time 5-19 weeks) | Feasibility rate will be calculated as the number of participants who undergo surgical resection divided by the total number of participants in the Feasibility Analysis Set. The rate will be presented with an exact binomial 95% CI. |
| Secondary | Pill compliance - dabrafenib | Start of dabrafenib treatment to completion of treatment (total estimated time 9 weeks) | Dabrafenib pill compliance will be evaluated among participants who receive at least one dose of dabrafenib. For each participant and each agent, pill compliance will be calculated as the number of prescribed doses actually taken divided by the total number of doses prescribed and expressed as a percentage. Compliance will be calculated for dabrafenib based on pill diaries and returned pill counts. |
| Secondary | Pill compliance - trametinib | Start of trametinib treatment to completion of treatment (total estimated time 9 weeks) | Trametinib pill compliance will be evaluated among participants who receive at least one dose of trametinib. For each participant and each agent, pill compliance will be calculated as the number of prescribed doses actually taken divided by the total number of doses prescribed and expressed as a percentage. Compliance will be calculated for trametinib based on pill diaries and returned pill counts. |
| Secondary | Number of planned PULSAR pulses completed by participants | At completion of PULSAR (estimated to be 5 weeks) | The number of PULSAR fractions completed will be evaluated among participants who receive at least one PULSAR fraction. The number of completed fractions will be summarized. The proportion of participants who complete all planned PULSAR fractions will also be presented with an exact binomial 95% CI. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07886905
GET https://conductscience.org/api/trials/v1/NCT07886905/registered